ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
16 sept. 2021 08h30 HE | ARCA biopharma, Inc.
First international patient enrolled in BrazilTrial approximately 75% enrolledrNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTopline trial data anticipated in...
ARCA Logo - JPEG.jpg
ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th
16 août 2021 08h05 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA Logo - JPEG.jpg
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2
09 août 2021 08h00 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update
04 août 2021 16h15 HE | ARCA biopharma, Inc.
Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South AmericaTopline data anticipated in the fourth quarter of 2021 WESTMINSTER, Colo., Aug. 04, 2021 ...
Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology
28 juil. 2021 08h00 HE | ARCA biopharma, Inc.
Analysis in full patient cohort shows Gencaro effect compared to standard of careIn the GENETIC-AF entire cohort of heart failure patients treated with Gencaro, compared to patients treated with...
ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
13 juil. 2021 08h00 HE | ARCA biopharma, Inc.
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTrial expanded to South America, with regulatory approvals for Argentina and BrazilTarget trial enrollment...
ARCA Logo - JPEG.jpg
ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th
09 juil. 2021 08h00 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., July 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement
07 juil. 2021 08h00 HE | ARCA biopharma, Inc.
Provides exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID-19 and other indications WESTMINSTER, Colo., July 07, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma,...
ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update
11 mai 2021 16h15 HE | ARCA biopharma, Inc.
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 WESTMINSTER, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- ARCA...
Christopher Graybill Joins ARCA as Vice President, Clinical Development
05 mai 2021 16h05 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...